Dr. James H. Lee, MD
Ophthalmology (Ophthalmology Physician)
8580 Scarborough Dr, Suite 125
Colorado Springs, CO 80920
Who else practices at this address →
El Paso County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Illinois Medical College (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,016
Licensed in Colorado since 2006, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: Illinois Medical College
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CO license 45206 (first issued 2006; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uch-Memorial Health System Colorado Springs, CO
- Spanish Peaks Regional Health Center Walsenburg, CO
Medical groups
- James Lee MD PC (8 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,016
- Services billed
- 4,051
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient complete exam of visual system | 874 | 659 |
| Established patient office or other outpatient visit, 30-39 minutes | 598 | 275 |
| Imaging of retina | 593 | 363 |
| Established patient office or other outpatient visit, 20-29 minutes | 440 | 259 |
| Exam of visual field with extended testing | 407 | 333 |
| Imaging of optic nerve | 339 | 290 |
| Measurement of corneal curvature and depth of eye | 200 | 105 |
| Photography of the retina | 191 | 184 |
| Removal of cataract with insertion of prosthetic lens | 154 | 88 |
| New patient complete exam of visual system | 138 | 138 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Latanoprost Other prescribers in Colorado Springs, CO | 524 |
| Prednisolone Acetate Other prescribers in Colorado Springs, CO | 470 |
| Ketorolac Tromethamine Other prescribers in Colorado Springs, CO | 389 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Colorado Springs, CO | 354 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Colorado Springs, CO | 113 |
| Gatifloxacin | 72 |
| Lumigan (bimatoprost) Other prescribers in Colorado Springs, CO | 64 |
| Timolol Maleate Other prescribers in Colorado Springs, CO | 54 |
| Restasis (cyclosporine) Other prescribers in Colorado Springs, CO | 42 |
| Brimonidine Tartrate-Timolol (brimonidine tartrate/timolol) Other prescribers in Colorado Springs, CO | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 36 payments worth $1,195 in total to this clinician.
| Alcon Vision LLC | $635 |
|---|---|
| Rxsight Inc | $193 |
| Glaukos Corporation | $170 |
| Vantage Technology LLC | $53.56 |
| AbbVie Inc. | $52.32 |
| Oyster Point Pharma, Inc. | $47.24 |
| Bausch & Lomb Americas Inc. | $22.79 |
| Tarsus Pharmaceuticals, Inc. | $21.86 |
| Food and Beverage | $1,195 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $106,508 in research payments for these studies, mostly to the institutions running them.
- A prospective, multicenter study of the glaukos istent infinite trabecular micro-bypass system model IS3 in subjects with mild to moderate primary open-angle glaucoma
Glaukos Corporation - Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
AbbVie Inc. · Completed · NCT03891446 - A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus
Glaukos Corporation - Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
AbbVie Inc. - A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
AbbVie Inc. - Follow-up of Eyes that Received Epithelium-on Corneal Collagen Cross-Linking Treatment in Study GLK-202-13
Glaukos Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.